Quantitative analysis of vitreous and plasma concentrations of brilliant blue G after use as a surgical adjuvant in chromovitrectomy
Phase 1
- Conditions
- Chromovitrevictomy for ERM and macular hole
- Registration Number
- JPRN-UMIN000020216
- Lead Sponsor
- Kyusyu University Hospital, Ohshima Hospital of Ophthalmology
- Brief Summary
BBG, which remained at low levels in the vitreous cavity, was not found in the systemic blood flow after the operation. Thus, any adverse effects of systemic BBG would be avoided.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1) Vitrectomized eye. 2) Has serious of digestive, circulatory, kidney, liver, or blood/coagulation complications 3) Had present and past uveitis or glaucoma 4) Has a history of drug hypersensitivity reactions for Triamcinolone acetonide, mydriatic, antibacterial eyedrops or local anesthetic. 5) Has a history of drug or alcohol abuse 6) Had taken this clinical trial 7) Will take part in in another clinical trial or clinical research during this clinical trial 8) Is deemed unsuitable for this trial by PI or SI
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentrations of BBG after chromovitrectomy
- Secondary Outcome Measures
Name Time Method Vitreous concentrations of BBG after chromovitrectomy